Drug Trial Radar · NCT04759534
Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia
Last checked: Nov 19, 2026Latest source record: Aug 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Actual
Start
Sep 10, 2020
Primary completion
Oct 30, 2021
Study completion Nov 30, 2021
Sponsor
- Lead sponsor
- Shenzhen People's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Innovent Biopharmaceutical Co., Ltd.
- First posted
- Feb 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study plans to enroll several patients with heterozygous familial hypercholesterolemia, randomly assigned to different dose groups, and randomly receiving subcutaneous injection of IBI306150 mg or placebo every two weeks: or subcutaneous injection of IBI306 450mg every four weeks (n=49) or placebo (n=25) treatment, treatment lasted for 12 weeks. During randomization, the LDL-C level (\<4.8mmol/L or ≥4.8mmol/L) observed during the screening period visit (VI), and whether ezetimibe was used for stratification. After 12 weeks, each group entered the 12-week open-period treatment, in which subjects in the IBI306 group continued to receive IBI306 treatment, and subjects in the placebo group stopped using placebo and received IBI306 treatment. The exploratory endpoint is the population pharmacokinetic characteristics of IBI306 in Chinese heterozygous familial hypercholesterolemia population.
Conditions
- Efficacy and Safety
- Heterozygous Familial Hypercholesterolemia
- PCSK9
Interventions
protein convertase subtilisin/kexin type 9 inhibitorBiological
IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- LDL-CTime frame: 12 weeks after baseline
- LDL-CTime frame: 24 weeks after baseline
- non HDL-CTime frame: 12 weeks after baseline
- non HDL-CTime frame: 24 weeks after baseline
- ApoBTime frame: 12 weeks after baseline
- ApoBTime frame: 24 weeks after baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
xili People's Hospital
Shenzhen, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.